Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ESA Use In Chronic Kidney Disease Will Get Second MedCAC Review

This article was originally published in The Pink Sheet Daily

Executive Summary

Medicare coverage of Amgen's Aranesp and other erythropoiesis-stimulating agents in chronic kidney disease is the topic for a meeting by the Medicare Evidence Development and Coverage Advisory Committee on Jan. 19.

You may also be interested in...



Pharma News, In Brief

Medicare ESRD Performance Measures

Pharma News, In Brief

Medicare ESRD Performance Measures

Aranesp Awaits Label Transplant As Committee Mulls Alternate Trial Designs

Amgen avoided an immediate setback when a Cardiovascular and Renal Drugs Advisory Committee meeting on Oct. 18 voted against further restrictions on the use of Aranesp (darbepoetin alfa) in chronic kidney disease (CKD) patients.

Related Content

Topics

UsernamePublicRestriction

Register

PS071365

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel